Cardioprotective Effects of VCP Modulator KUS121 in Murine and Porcine Models of Myocardial Infarction
Overview
Authors
Affiliations
No effective treatment is yet available to reduce infarct size and improve clinical outcomes after acute myocardial infarction by enhancing early reperfusion therapy using primary percutaneous coronary intervention. The study showed that Kyoto University Substance 121 (KUS121) reduced endoplasmic reticulum stress, maintained adenosine triphosphate levels, and ameliorated the infarct size in a murine cardiac ischemia and reperfusion injury model. The study confirmed the cardioprotective effect of KUS121 in a porcine ischemia and reperfusion injury model. These findings confirmed that KUS121 is a promising novel therapeutic agent for myocardial infarction in conjunction with primary percutaneous coronary intervention.
The effect of KUS121, a novel VCP modulator, against ischemic injury in random pattern flaps.
Yoshimoto K, Ikeguchi R, Noguchi T, Ando M, Sakamoto D, Iwai T PLoS One. 2024; 19(12):e0299882.
PMID: 39724048 PMC: 11671021. DOI: 10.1371/journal.pone.0299882.
The protein segregase VCP/p97 promotes host antifungal defense via regulation of SYK activation.
Shao Z, Wang L, Cao L, Chen T, Jia X, Sun W PLoS Pathog. 2024; 20(10):e1012674.
PMID: 39471181 PMC: 11548748. DOI: 10.1371/journal.ppat.1012674.
Lahiri S, Lu J, Aguilar-Sanchez Y, Li H, Moreira L, Hulsurkar M J Mol Cell Cardiol. 2024; 194:85-95.
PMID: 38960317 PMC: 11519832. DOI: 10.1016/j.yjmcc.2024.06.011.
Zhu H, Wang J, Xin T, Chen S, Hu R, Li Y Cell Mol Life Sci. 2023; 80(8):213.
PMID: 37464072 PMC: 11072740. DOI: 10.1007/s00018-023-04863-z.
Guan S, Yu Y, Li B, Gu H, Chen L, Wang N Pharmgenomics Pers Med. 2023; 16:201-217.
PMID: 36945217 PMC: 10024908. DOI: 10.2147/PGPM.S398522.